You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.
Daiichi Sankyo plans to use the ERS IP to support its own R&D initiatives to address areas of unmet medical need, the company said.
The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.
Invivoscribe submitted the LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.
The company submitted the test to Japanese regulators for approval as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.
The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.
HTG will use its EdgeSeq platform to develop a multi-target mRNA assay for Daiichi Sankyo and to profile tumor samples for Centre Léon Bérard.
MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.
The large PGx analysis might provide welcome data for those already supportive of genotyping in the context of warfarin, but will it convince detractors?
NEW YORK (GenomeWeb) – Agendia today announced a new deal with Daiichi Sankyo to use Agendia's oncology biomarker technology to evaluate new drugs from the Japanese drug firm currently in clinical trials.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.